Scholar Rock Holding Corp (SRRK) director logs share buys and warrant exercise

Rhea-AI Filing Summary

Scholar Rock Holding Corp director Srinivas Akkaraju reported multiple transactions in the company’s common stock. On 10/07/2025, he indirectly purchased 12,796, 12,400 and 4,403 shares through Samsara Opportunity Fund, L.P. at weighted average prices of $39.31, $40.18 and $40.97 per share, increasing that fund’s indirect holdings to 530,038 shares.

On 12/12/2025, warrants with a $7.35 exercise price were exercised through Samsara BioCapital, L.P., resulting in the acquisition of 1,064,804 shares of common stock and raising that entity’s indirect holdings to 6,367,614 shares, with the related warrant position reduced to zero. The form also shows 21,132 shares of common stock held directly. Footnotes explain that the 10/07/2025 purchase prices are weighted averages for multiple trades within specified price ranges.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AKKARAJU SRINIVAS

(Last) (First) (Middle)

628 MIDDLEFIELD ROAD

(Street)

PALO ALTO CA 94301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Scholar Rock Holding Corp [ SRRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2025		P		12,796	A	$39.31(1)	513,235	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	10/07/2025		P		12,400	A	$40.18(3)	525,635	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	10/07/2025		P		4,403	A	$40.97(4)	530,038	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	12/12/2025		X		1,064,804	A	$7.35	6,367,614	I	By Samsara BioCapital, L.P.(5)
Common Stock								21,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to Purchase Common Stock	$7.35	12/12/2025		X			1,064,804	06/22/2022	12/31/2025	Common Stock	1,064,804	$0	0	I	By Samsara BioCapital LP(5)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $38.85 to $39.849 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

2. Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $39.8512 to $40.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $40.87 to $41.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

5. Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

	/s/ Srinivas Akkaraju	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Scholar Rock (SRRK) disclose in this filing?

The filing shows that director Srinivas Akkaraju reported open-market purchases of Scholar Rock common stock on 10/07/2025 and the exercise of warrants on 12/12/2025, resulting in increased indirect and direct share ownership.

How many Scholar Rock (SRRK) shares were bought on 10/07/2025 and at what prices?

On 10/07/2025, the reporting person indirectly bought 12,796, 12,400 and 4,403 shares of common stock through Samsara Opportunity Fund, L.P. at weighted average prices of $39.31, $40.18 and $40.97 per share, respectively.

What warrant exercise involving Scholar Rock (SRRK) shares is reported?

The filing reports that on 12/12/2025, warrants to purchase common stock with an exercise price of $7.35 were exercised for 1,064,804 underlying shares through Samsara BioCapital, L.P., and the number of such warrants beneficially owned after the transaction became 0.

How many Scholar Rock (SRRK) shares are indirectly held after these transactions?

Following the reported transactions, Samsara Opportunity Fund, L.P. indirectly holds 530,038 shares of Scholar Rock common stock, and Samsara BioCapital, L.P. indirectly holds 6,367,614 shares, over which the reporting person has voting and investment power.

How many Scholar Rock (SRRK) shares does the reporting person hold directly?

In addition to indirect holdings through investment entities, the form lists 21,132 shares of Scholar Rock common stock held in direct ownership.

Does the filing explain how the reported Scholar Rock (SRRK) trade prices were calculated?

Yes. Footnotes state that the prices of $39.31, $40.18 and $40.97 reported for the 10/07/2025 purchases are weighted average prices from multiple trades within specified price ranges, and detailed per-trade data is available upon request.